<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518553</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiPudongH4</org_study_id>
    <nct_id>NCT04518553</nct_id>
  </id_info>
  <brief_title>Plasma Purification and Chronic Hepatitis B</brief_title>
  <official_title>Shanghai Pudong Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pudong Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pudong Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of nucleoside analogues （HA） alone and plasma purification +HA in&#xD;
      reducing HBV viral load.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) is a major disease harmful to human health and an important cause&#xD;
      of liver cirrhosis and liver cancer. Hepatitis B virus (HBV) cccDNA exists for a long time in&#xD;
      the liver of infected persons and serves as a template for HBV replication, which makes it&#xD;
      difficult to eradicate HEPATITIS B virus infection. Antiviral drugs are commonly used&#xD;
      clinically, including interferon and nucleoside analogues, but there are problems of&#xD;
      recurrence and drug resistance. These drugs are not directly targeted at cccDNA and are&#xD;
      therefore inefficient at reducing cccDNA. How to quickly and efficiently reduce the viral&#xD;
      load of HBV-DNA, inhibit THE TRANSCRIPTION of HBV-CCCDNA RNA, and promote the negative&#xD;
      conversion of HBeAg is an urgent problem to be solved at present, so it is particularly&#xD;
      important to find other more effective drugs or methods. Plasma purification is a new&#xD;
      treatment method in which the pathogenic factors (hepatitis B virus, etc.) are trapped in the&#xD;
      hollow fibers by special membrane materials and removed. Therefore, this study adopts the&#xD;
      randomized control method to explore the effect of plasma purification on HBV clearance,&#xD;
      aiming to explore the effectiveness and safety of plasma purification in reducing HBV DNA&#xD;
      viral load and inhibiting HBV cccDNA RNA transcription, so as to provide new treatment ideas&#xD;
      and methods for future treatment of hepatitis B virus infection, which is beneficial to the&#xD;
      society and individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 23, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of HBV(hepatitis B virus) HBeAg is serologically negative</measure>
    <time_frame>2 years</time_frame>
    <description>serological examination every three months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of HBV-DNA virus load is undetected</measure>
    <time_frame>2 years</time_frame>
    <description>serological examination by compared of HAs with HAs+plasma purification treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of hepatitis B virus cccDNA RNA transcription becomes undetectedly</measure>
    <time_frame>2 years</time_frame>
    <description>serological examination every three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis B virus HBsAg serological transformation is negative</measure>
    <time_frame>2 years</time_frame>
    <description>serological examination every three months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>active control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active interference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active comarator using antiviral drug of nucleoside analogues</intervention_name>
    <description>using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.</description>
    <arm_group_label>active control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HA+purification</intervention_name>
    <description>Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.</description>
    <arm_group_label>active interference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of Chronic hepatitis B Disease&#xD;
&#xD;
          2. hepatitis B virus HBeAg is positive&#xD;
&#xD;
          3. hepatitis B virus HBV-DNA virus load is more than 100000cps/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypotension&#xD;
&#xD;
          2. Cardiopulmonary insufficiency&#xD;
&#xD;
          3. Coagulation disorders&#xD;
&#xD;
          4. Heparin allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Min Jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Min Jin, MD</last_name>
    <phone>13917232915</phone>
    <email>hmjgli@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiu Hong Yang, MD</last_name>
    <phone>18317070897</phone>
    <email>18317070897@163.com</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pudong Hospital</investigator_affiliation>
    <investigator_full_name>Jin HM, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

